Trapeziometacrpal osteoarthritis Musculoskeletal Diseases Arthrosis, unspecified
Conditions
Interventions
All patients underwent one cycle of three weekly intra-articular (i.a.) injections of 0.8 mL (10 mg/mL) of Hyalgan® (hyaluronan) (MW 500? 730 KDa) using a dorsolateral approach after palpating the joi
Sponsors
Hospital Accredited Private Villa Regina [L' Ospedale Privato Accreditato Villa Regina] (Italy)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients treated with Hyalgan® in the period within January 2000 and December 2002 2. Patients presenting symptomatic trapeziometacarpal osteoarthritis stated by Kellgren and Lawrence grade scale 3. Patients with at least 6 months of follow-up 4. Patients aged within 50 and 80 years
Exclusion criteria
Exclusion criteria: 1. Arthritic or metabolic pathologies and/or serious trauma 2. Less than 6 months of follow-up 3. Clinically relevant differences in the treatment within enrolled patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At baseline and at each subsequent observation times at 1, 3 and 6 months after the treatment, the efficacy and safety parameters were assessed by the investigator and by patients. The following variables were considered and recorded during the visits: 1. Anamnestic and demographic data (only at baseline) 2. Spontaneous pain on movement 3. Provoked pain on movement 4. Pain during night and day 5. Morning stiffness 6. Physician?s global assessment 7. Patient?s global assessment 8. Palmar and radial abduction 9. Pinch strength 10. Nonsteroidal Antiinflammatory Drugs (NSAIDs) intake 11. Tolerability of the product | — |
Secondary
| Measure | Time frame |
|---|---|
| Local or systemic safety profile of Hyalgan® | — |
Countries
Italy
Outcome results
None listed